title: [Osteoporosis: Optimizing treatment strategy].
abstract: Selection of patients for treatment is based on the assessment of their absolute fracture risk over 10 years. Assessment of fracture risk includes not only DXA measurement and age, the two principal risk factors, but also other clinical risk factors. The main goal of postmenopausal osteoporosis treatment is to reduce the risk of fragility fractures. Choice of treatment is based on drug properties, demonstrated in clinical trials, and patients' specific fracture risks. The minimum duration of treatment is 4-5 years, after which individual fracture risk must be reevaluated. Combinations of available drugs are not recommended for treatment of postmenopausal osteoporosis.
authors.affiliation: Service de rhumatologie, Inserm E0366, Saint-Etienne (42). thierry.thomas@univ-st-etienne.fr
authors.forename: Thierry
authors.initials: T
authors.lastname: Thomas
mesh_terms: D000367:Age Factors; D000368:Aged; D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002136:Calcium, Dietary / Q000008:administration & dosage / Q000627:therapeutic use; D018849:Controlled Clinical Trials as Topic; D003720:Densitometry; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D050723:Fractures, Bone / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000627:therapeutic use; D018579:Patient Selection; D012307:Risk Factors; D016103:Spinal Fractures / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D019379:Teriparatide / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014815:Vitamins / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D004164:Diphosphonates; D010281:Parathyroid Hormone; D014815:Vitamins; D019379:Teriparatide; D019386:Alendronate